Sanofi to Develop Biomunex Bi-, Multi-Specific Antibodies for Immuno-Oncology and Other Areas

"Sanofi will use Biomunex Pharmaceuticals’ proprietary BiXAb® platform for generating and optimizing bi- and multi-specific antibodies to develop new treatments in immuno-oncology and other therapeutic areas, Biomunex said today. The companies have signed a licensing agreement whose value was not disclosed. The collaboration with Sanofi is the first partnership for Biomunex, a Paris-based biotech founded in 2014 to discover and develop innovative bispecific antibody therapeutics that combine bispecific antibodies with checkpoint inhibitors to address unmet medical needs, with a focus on cancer..." Lire la suite